M
María Santos Martínez
Researcher at GlaxoSmithKline
Publications - 29
Citations - 2824
María Santos Martínez is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Plasmodium falciparum & Plasmodium berghei. The author has an hindex of 21, co-authored 29 publications receiving 2357 citations. Previous affiliations of María Santos Martínez include Children's Hospital Oakland Research Institute & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
Chemical genetics of Plasmodium falciparum.
W. Armand Guiguemde,Anang A. Shelat,David Bouck,Sandra Duffy,Gregory J. Crowther,Paul H. Davis,David C. Smithson,Michele Connelly,Julie Clark,Fangyi Zhu,María Belén Jiménez-Díaz,María Santos Martínez,Emily Wilson,Abhai K. Tripathi,Jiri Gut,Elizabeth R. Sharlow,Ian Bathurst,Farah El Mazouni,Joseph W. Fowble,Isaac P. Forquer,Paula L. McGinley,Steve Castro,Iñigo Angulo-Barturen,Santiago Ferrer,Philip J. Rosenthal,Joseph L. DeRisi,David J. Sullivan,John S. Lazo,David S. Roos,Michael K. Riscoe,Margaret A. Phillips,Pradipsinh K. Rathod,Wesley C. Van Voorhis,Vicky M. Avery,R. Kiplin Guy +34 more
TL;DR: A phenotypic forward chemical genetic approach to discover new antimalarial chemotypes and structures and biological activity of the entire library are disclosed, many of which showed potent in vitro activity against drug-resistant P. falciparum strains.
Journal ArticleDOI
A novel multiple-stage antimalarial agent that inhibits protein synthesis
Beatriz Baragaña,Irene Hallyburton,Marcus C. S. Lee,Marcus C. S. Lee,Neil R. Norcross,Raffaella Grimaldi,Thomas D. Otto,William R. Proto,Andrew M. Blagborough,Stephan Meister,Grennady Wirjanata,Andrea Ruecker,Leanna M. Upton,Tara S. Abraham,Mariana Justino de Almeida,Anupam Pradhan,Achim Porzelle,María Santos Martínez,Judith M. Bolscher,Andrew Woodland,Suzanne Norval,Fabio Zuccotto,John Thomas,Frederick R. C. Simeons,Laste Stojanovski,Maria Osuna-Cabello,Patrick M. Brock,Thomas S. Churcher,Katarzyna A. Sala,Sara E. Zakutansky,María Belén Jiménez-Díaz,Laura M. Sanz,Jennifer Riley,Rajshekhar Basak,Michael Campbell,Vicky M. Avery,Robert W. Sauerwein,Koen J. Dechering,Rintis Noviyanti,Brice Campo,Julie A. Frearson,Iñigo Angulo-Barturen,Santiago Ferrer-Bazaga,Francisco-Javier Gamo,Paul G. Wyatt,Didier Leroy,Peter Siegl,Michael J. Delves,Dennis E. Kyle,Sergio Wittlin,Jutta Marfurt,Ric N. Price,Robert E. Sinden,Elizabeth A. Winzeler,Susan A. Charman,Lidiya Bebrevska,David W. Gray,Simon Campbell,Alan H. Fairlamb,Paul Willis,Julian C. Rayner,David A. Fidock,Kevin D. Read,Ian H. Gilbert +63 more
TL;DR: DDD107498 was developed from a screening programme against blood-stage malaria parasites and its molecular target has been identified as translation elongation factor 2 (eEF2), which is responsible for the GTP-dependent translocation of the ribosome along messenger RNA, and is essential for protein synthesis.
Journal ArticleDOI
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria
Margaret A. Phillips,Julie Lotharius,Kennan C. Marsh,John H. White,Anthony Dayan,Karen L. White,Jacqueline W. Njoroge,Farah El Mazouni,Yanbin Lao,Sreekanth Kokkonda,Diana R. Tomchick,Xiaoyi Deng,Trevor Laird,Sangeeta N. Bhatia,Sandra March,Caroline L. Ng,David A. Fidock,Sergio Wittlin,Sergio Wittlin,Maria J. Lafuente-Monasterio,Francisco Javier Gamo Benito,Laura Maria Sanz Alonso,María Santos Martínez,María Belén Jiménez-Díaz,Santiago Ferrer Bazaga,Iñigo Angulo-Barturen,John N. Haselden,James B. Louttit,Yi Cui,Arun Sridhar,Anna Marie Zeeman,Clemens H. M. Kocken,Robert W. Sauerwein,Koen J. Dechering,Vicky M. Avery,Sandra Duffy,Michael J. Delves,Robert E. Sinden,Andrea Ruecker,Kristina S. Wickham,Rosemary Rochford,Janet Gahagen,Lalitha V. Iyer,Ed Riccio,Jon C. Mirsalis,Ian Bathhurst,Thomas Rueckle,Xavier C. Ding,Brice Campo,Didier Leroy,M. John Rogers,Pradipsinh K. Rathod,Jeremy N. Burrows,Susan A. Charman +53 more
TL;DR: DSM265, a triazolopyrimidine-based inhibitor of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH), is the first DHODH inhibitor to reach clinical development for treatment of malaria as discussed by the authors.
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria
Margaret A. Phillips,Julie Lotharius,Kennan C. Marsh,John H. White,A. Dayan,Karen L. White,Jacqueline W. Njoroge,F. El Mazouni,Y. Lao,Sreekanth Kokkonda,Diana R. Tomchick,Xiaoyi Deng,T. Laird,Caroline L. Ng,David A. Fidock,Sergio Wittlin,Maria Jose Lafuente-Monasterio,Francisco Javier Gamo Benito,L. M. S. Alonso,María Santos Martínez,María-Belén Jiménez-Díaz,Santiago Ferrer Bazaga,Iñigo Angulo-Barturen,John N. Haselden,James B. Louttit,Yi Cui,Arun Sridhar,Anne-Marie Zeeman,Clemens H. M. Kocken,Robert W. Sauerwein,Koen J. Dechering,Vicky M. Avery,Sandra Duffy,Michael J. Delves,Robert E. Sinden,Andrea Ruecker,Kristina S. Wickham,Rosemary Rochford,Janet Gahagen,Lalitha V. Iyer,Ed Riccio,Jon C. Mirsalis,I. Bathhurst,Thomas Rueckle,Xavier C. Ding,Brice Campo,Didier Leroy,M. J. Rogers,Pradipsinh K. Rathod,Jeremy N. Burrows,Susan A. Charman,Sangeeta N. Bhatia,Sandra March-Riera +52 more
TL;DR: The excellent safety profile, blood- and liver-stage activity, and predicted long half-life in humans position DSM265 as a new potential drug combination partner for either single-dose treatment or once-weekly chemoprevention of malaria.
Journal ArticleDOI
(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium
María Belén Jiménez-Díaz,Daniel H. Ebert,Yandira G. Salinas,Anupam Pradhan,Adele M. Lehane,Marie-Eve Myrand-Lapierre,Kathleen O’Loughlin,David M. Shackleford,Mariana Justino de Almeida,Angela K. Carrillo,Julie Clark,Adelaide S. M. Dennis,Jonathon Diep,Xiaoyan Deng,Sandra Duffy,Aaron N. Endsley,Greg Fedewa,W. Armand Guiguemde,María G. Gómez,Gloria Holbrook,Jeremy A. Horst,Charles C. Kim,Jian Liu,Marcus C. S. Lee,Amy Matheny,María Santos Martínez,Gregory M. Miller,Ane Rodríguez-Alejandre,Laura M. Sanz,Martina Sigal,Natalie J. Spillman,Philip D. Stein,Zheng Wang,Fangyi Zhu,David Waterson,Spencer Knapp,Anang A. Shelat,Vicky M. Avery,David A. Fidock,Francisco-Javier Gamo,Susan A. Charman,Jon C. Mirsalis,Hongshen Ma,Santiago Ferrer,Kiaran Kirk,Iñigo Angulo-Barturen,Dennis E. Kyle,Joseph L. DeRisi,David M. Floyd,R. Kiplin Guy +49 more
TL;DR: The results demonstrate that targeting ATP4 has great potential to deliver useful drugs for malaria eradication and suggest that inhibitors of PfATP4 have highly attractive features for fast-acting antimalarials to be used in the global eradication campaign.